mug131 Antibody

Introduction to MUC13 Antibody

MUC13 (mucin 13, cell surface-associated) is a transmembrane glycoprotein overexpressed in gastrointestinal cancers, including colorectal and gastric carcinomas . Anti-MUC13 antibodies are critical tools for:

• Detecting aberrant MUC13 expression in cancer diagnostics

• Studying mucin-mediated signaling pathways

• Developing targeted immunotherapies

Key characteristics of MUC13:

Proteintech 29832-1-AP (Rabbit Polyclonal)1

Abcam ab235450 (Rabbit Monoclonal [EPR21901])7

Diagnostic Utility

• Colorectal Cancer: MUC13 antibodies show strong apical cytoplasmic staining in 85% of colorectal adenocarcinomas, correlating with advanced tumor stage .

• Gastric Cancer: Overexpression linked to lymph node metastasis and poor prognosis (IHC studies) .

Functional Insights

• MUC13 interacts with HER2 and EGFR, promoting oncogenic signaling .

• Antibody-dependent cellular phagocytosis (ADCP) efficacy depends on epitope proximity to the cell membrane, as demonstrated in engineered Jurkat cell models .

Therapeutic Trials

While no MUC13-specific therapies are FDA-approved, parallel research on MUC1-targeting antibodies provides mechanistic insights:

Challenges and Future Directions

• Glycosylation Variability: Observed molecular weight discrepancies (55 kDa vs. 70–120 kDa) complicate blot interpretation .

• Therapeutic Potential: Engineered antibodies with membrane-proximal epitope binding may enhance ADCC/ADCP efficacy .

• Biomarker Development: Soluble TA-MUC1 levels are being explored as predictive biomarkers in combination therapies .